VolumeVol. 53 • Number No. 3 • July - September 2015 Back

Original Paper

​​​​​​​First Line Anti-Tuberculosis Drug Resistance Pattern in Mycobacterium tuberculosis Isolates at the University of Santo Tomas Hospital from 2003-2013

Authors: Caroline Bernadette O. King Kay, Lennie D. Quimio, Julie Christie G. Visperas, Jose Hesron D. Morfe, Evelina N. Lagamayo

DOI: 10.65564/pjim.ec3f9e9e6b

Date of Publication: September 2015

Abstract

Introduction: Development of drug resistance is one of the most important barriers in achieving global control of tuberculosis (TB). Continuous surveillance, such as observation of susceptibility and resistance patterns to anti-TB drugs, together with nationwide programs aimed at TB case identification, treatment and control, physician and patient education, is a valuable tool in the goal towards reducing TB prevalence and mortality.

Objective: It is the aim of this study to determine the prevalence rate and resistance pattern of first line anti-tuberculosis drugs in a tertiary hospital in Manila, Philippines

Materials and Methods: Records of specimens submitted for Mycobacterium tuberculosis (MTB) culture and sensitivity, using BACTECTM MGITTM 960 SIRE Kit and PZA Kit, at the Section of Clinical Pathology, University of Santo Tomas Hospital, were reviewed. Isolates cultured for MTB were subjected to sensitivity studies to rifampicin (R), isoniazid (H), ethambutol (E), pyrazinamide (Z) and streptomycin (S).

Results: A total of 546 specimens were cultured for MTB and sent for sensitivity studies. Majority of the specimens were from pulmonary sources (77%). Overall resistance rate was 52.38% (n=286). One-drug resistance was 23.26% (n= 127; highest with R followed by H); two-drug resistance was 15.38% (n=84; highest with H-R); three-drug resistance was 8.61% (n=47; highest with H-R-E and H-R-S); four-drug resistance was 4.58% (n=25; highest with H-R-E-S) and five-drug resistance (H-R-E-S-Z) rate was 0.55% (n=3).

Conclusion: The University of Santo Tomas Hospital, as a referral facility, is encountering an increasing number of drug-resistant tuberculosis from 2003 to 2013.

Keywords: Anti-tuberculosis drugs; Drug Resistance; Mycobacterium tuberculosis; University of Santo Tomas Hospital  

Details Download PDF Citation

References

  1. World Health Organization Global Tuberculosis Report 2014. Geneva Switzerland: 2014.
  2. Macalalad, N. Philippine Drug Resistance Survey 2012-2013. (Unpublished)
  3. Gler MT, Guilatco RS, Guray CV, Tupasi TE. Screening outcomes from patients with suspected multi-drug resistant tuberculosis: lessons learned in the Philippines. Int J Lung Dis 16 (10): 1326-1330; 2012.
  4. Okhado A, Aguiman L, Adlawan S, et al. Tuberculosis drug resistance and treatment outcomes under DOTS in large cities in the Philippines. Int J Tuberc Lung Dis 10 (3): 283-288; 2006.
  5. Fune J, Natividad MPR, Ong-Mateo M. Anti-TB drug resistance pattern at University of Santo Tomas Hospital from 1995-2000: Impact of changing and declining pattern. (Unpublished)
  6. Visperas J, Morfe J. Anti-TB drug resistance pattern at University of Santo Tomas Hospital from 2003-2007: Impact of changing and declining pattern. Respirology 13 (5): A108.
  7. Harkin T, Condos R. Treatment of Multi-Drug Resistant Tuberculosis. In: Tuberculosis, 2nd edition. Boston, Little Brown, 2004; p729.
  8. Serafino Wani, RL. Tuberculosis 2: Pathophysiology and Microbiology of Pulmonary Tuberculosis. South Sudan Medical Journal 6:10-12; 2013.
  9. Gillespie, SH. Evolution of Drug Resistance in Mycobacterium Tuberculosis: Clinical and Molecular Perspective. Antimicrobial Agents and Chemotherapy 46: 267-74; 2002.
  10. Grange, JM. Drug Resistance and Tuberculosis Elimination. Bulletin International Union Against Tuberculosis and Lung Diseases 65: 57; 1990.
  11. Zhang Y, Heym B, Allen B. et. al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358;1992.
  12. Barry CE III, Lee R, Mdluli K, et al. Mycolic Acids: structure, biosynthesis, and physiological functions. Progress in Lipid Research 37: 143-179; 1998.
  13. Sherman D, Mdluli K, Hickey M. et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272: 1641-43; 1996.
  14. Somoskov A, Parsons L, Salfinger M. The molecular basis of resistance to isoniazid, rifampin and pyrazinamide in Mycobacterium tuberculosis. Review. Respiratory Research 2:164-68; 2001.
  15. Benerjee, A, Dubnau A, Quemard, V et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230; 1994.
  16. MIese L, Weisbrod J, Marcinkeviaene, R. et al. NADH dehydrogenase defects confer resistance to isoniazid and conditional lethality in Mycobacterium smegmatis. J Bacteriol Iso 180: 2459-2467; 1998.
  17. Da Silva P and Palomino J. Molecular basis and mechanisms of drug resistance in Mycobacterium Tuberculosis: classical and new drugs. Journal of Antimicrobial Therapy 66: 1417-1430; 2011.
  18. McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environment in vitro. American Review of Tuberculosis 70: 748-754; 1954.
  19. Ashok R., Kali A., Amad N. Multidrug Resistant Mycobacterium tuberculosis: Molecular Perspectives. Emerging Infectious Diseases 4:195-203; 1998.
  20. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. Molecular Genetics of Mycobacteria. Washington DC: ASM Press. 235-254. 2001.
  21. Telenti A. Philipp W, Sreevatsan S. et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Medicine 3: 567-570; 1997.
  22. Okamoto S, Tamaru A, Wakajima C et al. Loss of a conserved 7-methylguanosine modification in 16sRNA confers low level streptomycin resistance in bacteria. Molecular Microbiology 63: 1096-1106; 2007.
  23. Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug resistant tuberculosis. J Infect Public Health 7(2):75-91; 2014.